Diabetes

Diabetes is the flagship peer-reviewed journal of the American Diabetes Association, published since 1952, devoted to the physiology and pathophysiology of diabetes mellitus, and it holds a 2025 Journal Impact Factor of 9.3《糖尿病》（Diabetes）是美国糖尿病协会的旗舰同行评审期刊，1952 年创刊，专注糖尿病的生理学与病理生理学，2025 年影响因子为 9.3。

Scope

• The journal publishes original research on the physiology and pathophysiology of diabetes mellitus该刊发表关于糖尿病生理学与病理生理学的原创研究。
• It covers the pathogenesis of diabetes and of its complications其覆盖糖尿病及其并发症的发病机制。
• Normal and pathologic pancreatic islet function and intermediary metabolism are core subjects正常与病理状态下的胰岛功能及中间代谢是核心主题。
• Pharmacological mechanisms of drug and hormone action are within scope药物与激素作用的药理学机制属于其范围。
• Biochemical and molecular aspects of normal and abnormal biological processes are addressed其关注正常与异常生物学过程的生物化学与分子机制。
• Submitted manuscripts may report laboratory, animal or human research来稿可报道实验室、动物或人体研究。
• Diabetes education and the routine application of accepted therapeutic and diagnostic approaches to patients are not published糖尿病教育以及将公认诊疗手段常规应用于患者的研究不予发表。

History

• The journal was founded in 1952 and is the flagship research publication of the American Diabetes Association该刊 1952 年创办，是美国糖尿病协会的旗舰研究出版物。^[1]
• Its first editor-in-chief was Frank N. Allan of Boston, and he was followed by eleven successive editors其首任主编为波士顿的（Frank N. Allan），其后历经十一位主编。
• It is published monthly, and accepted articles are posted online ahead of print about five to six weeks after acceptance该刊按月出版，录用文章在录用后约五至六周先行在线预发表。
• Access is subscription-based, with an Open Choice option that lets authors make an article immediately free on payment of a charge该刊以订阅制为主，并提供（Open Choice）选项，作者付费后可使其文章立即免费开放。
• Its Journal Impact Factor moved from 9.461 in 2021 and 9.337 in 2022 to 7.5 in 2024 and 9.3 in 2025, with an acceptance rate of about 12.39%其影响因子由 2021 年的 9.461 与 2022 年的 9.337 变为 2024 年的 7.5 与 2025 年的 9.3，录用率约为 12.39%。

Editors

• David A. D'Alessio, professor of medicine at Duke University, is the editor-in-chief and was announced as incoming editor in November 2021（Duke University）医学教授（David A. D'Alessio）任主编，并于 2021 年 11 月被宣布为候任主编。
• His research concerns the regulation of glucose tolerance, gut hormones and the peptide GLP-1 in type 2 diabetes其研究关注血糖耐受的调控、肠道激素以及 2 型糖尿病中的肽类激素（GLP-1）。
• Norbert Stefan of the University of Tubingen and Bruce Verchere of the University of British Columbia serve as senior associate editors（University of Tubingen）的（Norbert Stefan）与（University of British Columbia）的（Bruce Verchere）任高级副编辑。
• Associate editors include Jonathan Campbell, Lisa Chow, Steven Crowley, Dawn Belt Davis, Carmella Evans-Molina and Rana Gupta, most of them based at North American universities副编辑包括（Jonathan Campbell）、（Lisa Chow）、（Steven Crowley）、（Dawn Belt Davis）、（Carmella Evans-Molina）与（Rana Gupta），多数任职于北美高校。
• The Board of Editors has about one hundred members from the United States, Europe and Asia, and the journal names a monthly Paper of the Month and runs the DiabetesBio podcast编委会约有 100 名成员，来自美国、欧洲与亚洲，该刊每月评选（Paper of the Month）并运营（DiabetesBio）播客。